Related references
Note: Only part of the references are listed.Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock
Satoshi Gando et al.
CRITICAL CARE (2015)
Recombinant Human Activated Protein C for Adults with Septic Shock A Randomized Controlled Trial
Djillali Annane et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation
Jean-Louis Vincent et al.
CRITICAL CARE MEDICINE (2013)
Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
Kazuma Yamakawa et al.
INTENSIVE CARE MEDICINE (2013)
Thrombosis as an intravascular effector of innate immunity
Bernd Engelmann et al.
NATURE REVIEWS IMMUNOLOGY (2013)
A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis
Satoshi Gando et al.
CRITICAL CARE (2013)
A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis
Satoshi Gando et al.
CRITICAL CARE (2013)
Drotrecogin Alfa (Activated) in Adults with Septic Shock
V. Marco Ranieri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome
Peter E. Morris et al.
BMC PULMONARY MEDICINE (2012)
Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis
Yoshihito Ogawa et al.
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY (2012)
Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia A Randomized Trial
Richard G. Wunderink et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
Kazuma Yamakawa et al.
CRITICAL CARE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Study of protein C, protein S, and antithrombin III in newborns with sepsis
Amal El Beshlawy et al.
PEDIATRIC CRITICAL CARE MEDICINE (2010)
Effectiveness of Treatments for Severe Sepsis A Prospective, Multicenter, Observational Study
Ricard Ferrer et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)
Fabian Jaimes et al.
CRITICAL CARE MEDICINE (2009)
Disseminated intravascular coagulation
Marcel Levi
CRITICAL CARE MEDICINE (2007)
Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis
Christopher Gonano et al.
CRITICAL CARE (2006)
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation
J Kienast et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
The interactions between inflammation and coagulation
CT Esmon
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Disseminated intravascular coagulation in sepsis
S Zeerleder et al.
CHEST (2005)
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
E Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
JF Dhainaut et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Sepsis and disseminated intravascular coagulation
M Levi et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2003)
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
E Abraham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis
BD Freeman et al.
SHOCK (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
GR Bernard et al.
CRITICAL CARE MEDICINE (2001)
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
E Abraham et al.
CRITICAL CARE MEDICINE (2001)
High-dose a randomized antithrombin III in severe sepsis -: A randomized controlled trial
BL Warren et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
